Vanguard Personalized Indexing Management LLC Has $2.22 Million Stake in GSK plc (NYSE:GSK)

Vanguard Personalized Indexing Management LLC lifted its position in shares of GSK plc (NYSE:GSK) by 13.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,524 shares of the pharmaceutical company’s stock after acquiring an additional 7,011 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in GSK were worth $2,215,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its holdings in GSK by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock valued at $65,883,000 after buying an additional 18,585 shares during the last quarter. Assetmark Inc. boosted its stake in GSK by 1,598.7% during the fourth quarter. Assetmark Inc. now owns 2,582 shares of the pharmaceutical company’s stock worth $96,000 after acquiring an additional 2,430 shares in the last quarter. Franklin Resources Inc. increased its position in GSK by 0.9% in the 4th quarter. Franklin Resources Inc. now owns 64,336 shares of the pharmaceutical company’s stock valued at $2,451,000 after buying an additional 602 shares in the last quarter. US Bancorp DE raised its position in shares of GSK by 3.3% during the fourth quarter. US Bancorp DE now owns 117,503 shares of the pharmaceutical company’s stock worth $4,355,000 after purchasing an additional 3,722 shares during the period. Finally, Avantax Planning Partners Inc. bought a new position in shares of GSK in the fourth quarter valued at $200,000. 15.74% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GSK has been the topic of a number of research analyst reports. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Berenberg Bank raised GSK to a “strong-buy” rating in a report on Thursday, June 20th. Citigroup raised GSK to a “strong-buy” rating in a report on Monday, June 24th. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, The Goldman Sachs Group began coverage on shares of GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective for the company. Four analysts have rated the stock with a hold rating, two have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $50.00.

GSK Price Performance

GSK stock opened at $40.80 on Friday. The firm has a 50 day simple moving average of $41.39 and a two-hundred day simple moving average of $41.70. The stock has a market cap of $84.55 billion, a PE ratio of 14.78, a P/E/G ratio of 1.41 and a beta of 0.66. GSK plc has a one year low of $33.67 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54.

GSK (NYSE:GSK) last released its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a return on equity of 51.48% and a net margin of 12.87%. The business had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. On average, analysts predict that GSK plc will post 4.15 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be paid a $0.3843 dividend. The ex-dividend date of this dividend is Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 3.77%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is currently 54.71%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.